Decibel Therapeutics
Decibel Therapeutics focuses on developing transformative treatments to restore and improve hearing and balance using regenerative and gene therapy strategies, with a strategic partnership with Regeneron Pharmaceuticals.
About Decibel Therapeutics
Decibel Therapeutics focuses on developing transformative treatments aimed at restoring and improving hearing and balance. The company employs regenerative and gene therapy strategies to address these needs. Their proprietary platform integrates single-cell genomics, bioinformatics analyses, and precision gene therapy technology. Their commitment extends to extensive clinical trials to ensure the safety and effectiveness of their treatments.
Strategic Partnership with Regeneron Pharmaceuticals
Decibel Therapeutics has a strategic partnership with Regeneron Pharmaceuticals to enhance its genetics research, drug discovery, and antibody development efforts. This collaboration aims to leverage Regeneron's capabilities, bolstering Decibel's pipeline of gene therapy programs and contributing to the development of novel hearing and balance disorder therapeutics.
Preclinical Gene Therapy Programs
Decibel Therapeutics is advancing a robust pipeline of preclinical gene therapy programs. These programs target both congenital and acquired hearing and balance disorders. They include therapies for congenital, monogenic hearing loss as well as hair cell regeneration and otoprotection. Notable products in development include DB-OTO, aimed at OTOF-related hearing loss, AAV.103 for GJB2-related hearing loss, and AAV.104 for STRC-related hearing loss.
DB-020: Prevention of Chemotherapy-Induced Hearing Loss
DB-020 is one of Decibel's key therapeutic developments, designed to combat hearing loss in cancer patients undergoing chemotherapy with cisplatin. It involves a novel formulation of sodium thiosulfate (STS) aimed at protecting patients from the ototoxic effects of cisplatin, thus preserving their hearing during cancer treatment.
Amplify™ Program: No-Charge Genetic Testing
The Amplify™ program by Decibel Therapeutics offers no-charge genetic testing for children diagnosed with auditory neuropathy. This initiative helps identify the genetic causes of hearing loss and supports the development of targeted gene therapies. Auditory neuropathy in children can be linked to a deficiency in otoferlin protein production, and gene therapy offers a promising solution for these patients.